David A. Eberhard

Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib

David A. Eberhard, Bruce E. Johnson, Lukas C. Amler et al. · Journal of Clinical Oncology · 2005 · 1.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Diverse somatic mutation patterns and pathway alterations in human cancers

Zhengyan Kan, Bijay S. Jaiswal, Jeremy Stinson et al. · Nature · 2010 · 1K citations

Medicine, Genetics, Oncology +16

Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non–Small-Cell Lung Cancer

Roy S. Herbst, David H. Johnson, Eric D. Mininberg et al. · Journal of Clinical Oncology · 2005 · 536 citations · Full text

Medicine, Oncology, Pharmacology +16

Epithelial versus Mesenchymal Phenotype Determines <i>In vitro</i> Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients

Robert L. Yauch, Thomas Januario, David A. Eberhard et al. · Clinical Cancer Research · 2005 · 491 citations · Full text

Medicine, Oncology, Pharmacology +17

Epidermal Growth Factor Receptor, Protein Kinase B/Akt, and Glioma Response to Erlotinib

Daphne A. Haas-Kogan, Michael D. Prados, Tarık Tihan et al. · JNCI Journal of the National Cancer Institute · 2005 · 467 citations · Full text

Medicine, Oncology, Pharmacology +17